Cytek Biosciences (CTKB) News Today $5.46 -0.03 (-0.55%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Should You Sell?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Here's What HappenedJanuary 17 at 8:16 AM | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Preliminary Full Year 2024 Revenue Results AnnouncedOn January 15, 2025, Cytek Biosciences, Inc. released its preliminary unaudited revenue for the fourth quarter and full year that concluded on December 31, 2024. The January 17 at 2:03 AM | americanbankingnews.comCytek Biosciences sees FY24 revenue $200M-$201M, consensus $204.71MJanuary 16, 2025 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Time to Sell?Cytek Biosciences (NASDAQ:CTKB) Shares Gap Down - Should You Sell?January 15, 2025 | marketbeat.comCytek Biosciences shares take a hit after Q4 sales miss estimatesJanuary 15, 2025 | in.investing.comCytek Biosciences Shares Fall On Low Preliminary 4Q RevenueJanuary 15, 2025 | marketwatch.comCytek Biosciences Announces Preliminary Full Year 2024 Revenue ResultsJanuary 15, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Hold Rating for Cytek Biosciences (CTKB)January 14, 2025 | markets.businessinsider.comBarclays PLC Has $1.12 Million Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB)Barclays PLC raised its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 333.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 201,359 shares of the company's stock after buyingJanuary 14, 2025 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Trading 5.9% Higher - Time to Buy?Cytek Biosciences (NASDAQ:CTKB) Shares Up 5.9% - Should You Buy?January 13, 2025 | marketbeat.comUpgrading Cytek Biosciences Stock On An Upcoming CatalystJanuary 9, 2025 | seekingalpha.comCytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comCytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest UpdateCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 3,690,000 shares, a drop of 6.6% from the November 30th total of 3,950,000 shares. Approximately 3.2% of the company's stock are sold short. Based on an average trading volume of 661,700 shares, the short-interest ratio is currently 5.6 days.December 31, 2024 | marketbeat.comCytek Biosciences board approves $50M stock repurchase programDecember 31, 2024 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) to Buyback $50.00 million in Stock Cytek Biosciences (NASDAQ:CTKB - Get Free Report) announced that its board has authorized a stock buyback program on Monday, December 30th, RTT News reports. The company plans to buyback $50.00 million in shares. This buyback authorization permits the company to reacquire up to 5.9% of its shares through open market purchases. Shares buyback programs are typically an indication that the company's management believes its stock is undervalued.December 30, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Stock Price Up 5.9% - Should You Buy?Cytek Biosciences (NASDAQ:CTKB) Trading Up 5.9% - Here's What HappenedDecember 30, 2024 | marketbeat.comCytek Biosciences Announces $50 Million Stock Repurchase Program for 2025December 30, 2024 | globenewswire.comGeode Capital Management LLC Buys 89,210 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)Geode Capital Management LLC boosted its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 3.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,668,004 shares of the company's stock after acquiring aDecember 30, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Acquired by Barclays PLCBarclays PLC boosted its position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 333.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 201,359 shares of the company's stock after buyinDecember 30, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by State Street CorpState Street Corp grew its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 4.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,167,501 shares of the company's stock after purchasing an additional 194December 23, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Stock Price Up 4.8% - Time to Buy?Cytek Biosciences (NASDAQ:CTKB) Trading 4.8% Higher - What's Next?December 18, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Stock Holdings Lessened by Wellington Management Group LLPWellington Management Group LLP lessened its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 6.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,007,139 shares of the company's stoDecember 16, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Shares Down 5.4% - Here's WhyCytek Biosciences (NASDAQ:CTKB) Trading Down 5.4% - Time to Sell?December 13, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 113,127 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)Charles Schwab Investment Management Inc. boosted its stake in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 12.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,030,962 shares of the company's stock aDecember 13, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Buys New Position in Cytek Biosciences, Inc. (NASDAQ:CTKB)Jacobs Levy Equity Management Inc. bought a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 182,713 shares ofDecember 9, 2024 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Cytek Biosciences (CTKB)November 26, 2024 | markets.businessinsider.comBrown Capital Management LLC Has $52.59 Million Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)Brown Capital Management LLC cut its position in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 16.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,493,474 shares of the company's stock after selling 1,893,910 shaNovember 21, 2024 | marketbeat.comCytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare ConferenceNovember 20, 2024 | globenewswire.comCytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards ProgramNovember 19, 2024 | globenewswire.comCautious Hold on Cytek Biosciences Amid Recovery and Growth OpportunitiesNovember 19, 2024 | markets.businessinsider.comCytek Biosciences, Inc. (NASDAQ:CTKB) Sees Large Decline in Short InterestCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a large decline in short interest in October. As of October 31st, there was short interest totalling 4,200,000 shares, a decline of 6.0% from the October 15th total of 4,470,000 shares. Approximately 3.6% of the company's shares are sold short. Based on an average daily volume of 673,900 shares, the short-interest ratio is presently 6.2 days.November 18, 2024 | marketbeat.comCytek Biosciences price target raised to $8.50 from $8 at Piper SandlerNovember 13, 2024 | markets.businessinsider.comPiper Sandler Issues Positive Forecast for Cytek Biosciences (NASDAQ:CTKB) Stock PricePiper Sandler boosted their target price on shares of Cytek Biosciences from $8.00 to $8.50 and gave the stock an "overweight" rating in a report on Monday.November 11, 2024 | marketbeat.comCytek Biosciences introduces ESP Detection Option for Cytek AuroraNovember 7, 2024 | markets.businessinsider.comCytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell SorterNovember 7, 2024 | globenewswire.comCytek Biosciences (NASDAQ:CTKB) Stock, Short Interest ReportNovember 7, 2024 | benzinga.comPositive Outlook and Buy Rating for Cytek Biosciences Amid Strong International Performance and Strategic ExpansionNovember 7, 2024 | markets.businessinsider.comCytek Biosciences Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | markets.businessinsider.comCytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ...November 6, 2024 | finance.yahoo.comCytek Biosciences’ Q3 2024 Financial HighlightsNovember 6, 2024 | markets.businessinsider.comCytek Biosciences (NASDAQ:CTKB) Shares Up 26.7% Following Strong EarningsCytek Biosciences (NASDAQ:CTKB) Stock Price Up 26.7% on Strong EarningsNovember 6, 2024 | marketbeat.comCytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | seekingalpha.comPreview: Cytek Biosciences's EarningsNovember 4, 2024 | benzinga.comWhat To Expect From Cytek Biosciences Inc (CTKB) Q3 2024 EarningsNovember 4, 2024 | finance.yahoo.comCytek Biosciences (CTKB) Scheduled to Post Quarterly Earnings on TuesdayCytek Biosciences (NASDAQ:CTKB) will be releasing earnings after the market closes on Tuesday, November 5, Zacks reports.October 30, 2024 | marketbeat.comCytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Up 5.4% in SeptemberCytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 4,300,000 shares, a growth of 5.4% from the September 15th total of 4,080,000 shares. Currently, 3.6% of the shares of the company are short sold. Based on an average daily trading volume, of 632,100 shares, the days-to-cover ratio is presently 6.8 days.October 17, 2024 | marketbeat.comMillennium Management LLC Raises Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB)Millennium Management LLC boosted its holdings in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 3,452.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 946,490 shares of the company's stock after purchasing an additional 919,845 shareOctober 12, 2024 | marketbeat.comSquarepoint Ops LLC Purchases 170,539 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB)Squarepoint Ops LLC lifted its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) by 1,013.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 187,361 shares of the company's stock afteOctober 7, 2024 | marketbeat.comRenaissance Technologies LLC Makes New $1.31 Million Investment in Cytek Biosciences, Inc. (NASDAQ:CTKB)Renaissance Technologies LLC acquired a new stake in Cytek Biosciences, Inc. (NASDAQ:CTKB - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 233,900 shares of the company's stock, valued at approximately $1,October 6, 2024 | marketbeat.comCytek Biosciences (NASDAQ:CTKB) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.com Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address CTKB Media Mentions By Week CTKB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTKB News Sentiment▼0.300.44▲Average Medical News Sentiment CTKB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTKB Articles This Week▼112▲CTKB Articles Average Week Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 10x Genomics News Transcat News Standard BioTools News EyePoint Pharmaceuticals News Aehr Test Systems News Senseonics News Allient News Quanterix News Quantum-Si News Nautilus Biotechnology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTKB) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTKB Stock Alerts